google search bladder cancer urocidin comes on top, with endo and bioniche, first time for the longest time ever. wonder which crap MM is going to invent this time. wonder how long this will take for full 450. at 500k who need care in US, this should not take that long.
Primary Outcome Measures:
- The primary objective of this study is to evaluate the efficacy of intravesical EN3348 as compared with mitomycin C in the treatment of subjects with recurrent or refractory NMIBC. [ Time Frame: 1 year ] [ Designated as safety issue: No ]
Secondary Outcome Measures:
- The secondary objective is to evaluate the safety of EN3348 as compared with mitomycin C in the treatment of subjects with BCG recurrent or refractory NMIBC. [ Time Frame: 1 year ] [ Designated as safety issue: Yes ]
| Estimated Enrollment: | 450 |
| Study Start Date: | November 2010 |
| Estimated Study Completion Date: | December 2013 |
| Estimated Primary Completion Date: | November 2013 (Final data collection date for primary outcome measure) |